期刊文献+

α-1,6-甘露糖转移酶基因敲除的毕赤酵母菌株构建及其用于融合蛋白HSA/GM-CSF表达的研究 被引量:17

A Pichia pastoris with α-1,6-mannosyltransferases Deletion and its Use in Expression of HSA/GM-CSF Chimera
下载PDF
导出
摘要 酵母对蛋白的糖基化修饰过程不同于哺乳动物,其特点为产生高甘露糖型糖基且易发生过度糖基化。本研究通过两步基因重组敲除目标基因的方法成功敲除了毕赤酵母中的α-1,6-甘露糖转移酶(och1p)基因,获得了och1敲除的菌株。以此为基础,构建了高效表达人血清白蛋白与粒细胞-巨噬细胞集落刺激因子融合蛋白(HSA/GM-CSF)的工程酵母,与野生型毕赤酵母表达的过度糖基化HSA/GM-CSF不同,och1敲除菌表达的该融合蛋白糖基化程度明显降低,这为该融合蛋白的开发提供了重要基础。och1敲除菌株的构建不仅提供了一个对糖蛋白进行低糖基化修饰的毕赤酵母表达系统,而且为进一步的酵母糖基工程改造提供了基础。 Yeast is a widely used host for recombinant protein expression.However,glycoproteins derived from yeast contain N-glycan of high mannose type and are usually hyperglycosylated.α-1,6-mannosyltransferases gene(och1)encodes the enzyme that initiates the first step of out-chain elongation of high mannose type N-glycan in yeast,which is different from that in human.So,a high efficient method to knockout target gene by two-step recombination was established and was used to delete och1.In the first recombinant,a plasmid with och1::ADE1 and ura3 gene was linearized in the downstream of och1 and inserted to the och1 site of P.pastoris genome,where the upstream and downstream of och1 were duplicated.In the second recombinant,the duplicated fragments of och1 were exchanged and the och1 deletion strains were selected on the plates containing 5-FOA,but no adenine.Then the och1 deletion strain was applied to express an human serum albumin(HSA)granulocyte-macrophage colony-stimulating factor(GM-CSF)chimera.Different with the hyperglycosylated HSA/GM-CSF chimera expressed in wild type P.pastoris,the chimera expressed in the och1 deletion strain,contained smaller N-glycan.The results suggested that the och1 mutant yeast may be more suitable for production of recombinant glycoproteins.And the och1 deletion strain could be used for further re-engineering to produce complex human glycoproteins.
出处 《生物工程学报》 CAS CSCD 北大核心 2007年第5期907-914,共8页 Chinese Journal of Biotechnology
关键词 α-1 6-甘露糖转移酶 基因敲除N-糖基化 粒细胞-巨噬细胞集落刺激因子 人血清白蛋白 毕赤酵母 α-1,6-mannosyltransferases,gene knockout,N-glycosylation,granulocyte-macrophage colony-stimulating factor,human serum albumin,Pichia pastoris
  • 相关文献

参考文献18

  • 1Helenius A,Aebi M.Intracellular funcation of N-linked glycans.Science,2001,291(5512):2364-2369.
  • 2Cregg JM,Cereghino JI,Shi J,et al.Recombinant protien expression in Pichia pastoris.Mol Biotechnol,2000,16(1):23 -52.
  • 3Hubbard SC,Ivatt RJ.Synthesis and processing of asparaginelinked oligosaccharides.Anna Rev Biochem,1981,50(7):555 -583.
  • 4Walsh G.Biopharmaceutical benchmarks-2003.Nature Biotechnol,2003,21(8):865-870.
  • 5Wildt S,Gerngross TU.The humanization of N-glycosylation pathways in yeast.Nature Microbiology,2005,3(2):119-128.
  • 6Li H,Sethuraman N,Stadheim TA,et al.Optimization of humanized IgGs in glycoengineered Pichia pastoris.Nature biotechnology,2006,24(2):210-215.
  • 7Hamiltone SR,Davidson R,Sethuraman N,et al.Humanization of yeast to produce complex terminally sialylated glycoproteins.Science,2006,313(8):1441-1443.
  • 8Bobrowicz P,Davidson RC,Li H,et al.Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris:production of complex humanized glycopreteins with terminal galactose.Glycobiology,2004,14(9):757-766.
  • 9Batova A,Kamps A,Gillies SD,et al.The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.Clin Cancer Res,1999,5(12):4259-4263.
  • 10Sainathan SK,Tu L,Bishnupuri KS,et al.PEGylated murine Granulocyte-macrophage colony-stimulating factor; production,purification,and characterization.Protein Expr Purif,2005,44(2):94-103.

二级参考文献20

  • 1Gutterman JU.Cytokine therapeutics:lessons from interferon alpha.Proc Natl Acad Sci U S A.1994,91(4):1198 - 1205
  • 2Garwala SS,Kirkwood JM.Potential uses of interferon alpha 2 as adjuvant therapy in cancer.Ann Surg Oncol,1995,2(4):365 -371
  • 3Hu KQ,Vierling JM,Redeker AG.Viral,host and interferonrelated factors modulating the effect of interferon therapy for hepatitis C virus infection.J Viral Hepat,2001,8(1) :1 - 18
  • 4Thevenot T,Regimbeau C,Ratziu V,Leroy V,Opolon P,Poynard T.Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients:1999 update.J Viral Hepat,2001,8(1):48-62
  • 5Zhi J,Teller SB,Satoh H,Koss-Twardy SG,Luke DR.Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2a given by subcutaneous injection in healthy male volunteers.J Clin Pharmacol,1995,35(3) :281 -284
  • 6Perry CM,Jarvis B.Peginterferon-alpha-2a (40 kD):a review of its use in the management of chronic hepatitis C.Drugs,2001,61(15) :2263 - 2288
  • 7Pedder SC.Pegylation of interferon alfa:structural and pharmacokinetic properties.Semin Liver Dis,2003,23 Suppl 1:19- 22
  • 8Glue P,Fang JW,Rouzier-Panis R et al.Pegylated interferonalpha2b:pharmacokinetics,pharmacodynamics,safety,and preliminary efficacy data.hepatitis C intervention therapy group.Clin Pharmacol Ther ,2000,68(5):556-567
  • 9Kamal SM,El Tawil AA,Nakano T et al.Peginterferon {alpha }-2b and ribavirin therapy in chronic hepatitis C genotype 4:impact of treatment duration and viral kinetics on sustained virological response.Gut,2005,54(6) :858 - 866
  • 10Bailon P,Palleroni A,Schaffer CA et al.Rational design of a potent,long-lasting form of interferon:a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.Bioconjug Chem,2001,12(2):195 - 202

共引文献15

同被引文献284

引证文献17

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部